

SWIXX COMPLETES STRATEGIC INVESTMENT FROM SK CAPITAL AND BAIN CAPITAL LIFE SCIENCES TO SUPPORT CONTINUED GLOBAL EXPANSION


Baar, Switzerland, June 1st, 2026 – Swixx Biopharma AG today confirmed the closing of the previously announced strategic investment by SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences sector.

Following the announcement in December 2025, the transaction has been completed on the terms previously disclosed.


SK Capital becomes the lead investor in Swixx Biopharma, as previously announced. In connection with the closing, Bain Capital Life Sciences has taken a minority investment position alongside SK Capital, further strengthening the partnership with additional expertise and global connectivity across both biotechs and large cap pharma. Bain Capital Life Sciences representatives shall serve on the Board of the company.

The completion of the transaction marks an important milestone in Swixx Biopharma’s continued development, providing additional resources and capabilities to support the company’s next phase of growth and RoW (Rest of World) expansion. Swixx will continue to operate with the same management team and strategic direction, further strengthening its position as a trusted multi-regional partner for leading biopharmaceutical companies.

Both the founders of Swixx and Biopas and Swixx’s senior management will remain significant shareholders, alongside SK Capital and Bain Capital Life Sciences -- joining long-standing investors HBM Healthcare Investments and Mérieux Equity Partners. The company’s founders, HBM and Mérieux Equity Partners will continue to actively serve on Swixx’s Board.


 **Jean-Michel Lespinasse, CEO of Swixx Biopharma**, said: “The closing of this investment represents an important step forward for Swixx and reinforces the strength of our strategy and platform. The addition of SK Capital and Bain Capital Life Sciences brings complementary expertise, international reach, and valuable industry networks that will support our continued expansion.

Together, we are well positioned to accelerate our growth and further strengthen our role as a trusted partner to biopharmaceutical companies, while continuing to improve access to innovative therapies for patients in the markets we serve.”

 **Aaron Davenport, Managing Director at SK Capital**, commented: “We are delighted to complete our investment in Swixx and to partner with the Swixx management team, Bain Capital Life Sciences, and the company’s founders and existing shareholders. Swixx has built a highly differentiated platform with a trusted reputation among biopharmaceutical partners, and we are committed to supporting the company as it continues to expand its geographic footprint and broaden access to medicines for patients.

Our investment underscores our strong conviction in Swixx’s existing strategy, management team, and partner-centric approach. As partners in Swixx’s next phase of growth, we are focused on supporting the company’s continued expansion while preserving the culture and operating model that have made it successful.”



 **Andrew Hack, MD, PhD, Partner at Bain Capital Life Sciences**, said: “We are proud to partner with SK Capital, the entire Swixx management team, and the distinguished founders and shareholders who have built Swixx into the leading company that it is today. We view Swixx as the ideal partner to help biopharma companies of all sizes bring their medicines to patients globally. We believe this investment has the potential to enable Swixx to further strengthen and broaden its offerings, unlocking additional opportunities for its customers and for health systems around the world.”

Advisors

Rothschild & Co. is serving as the sole financial advisor to SK Capital and Bär & Karrer and Kirkland & Ellis are serving as legal counsel. KPMG LLP provided advisory on financial, tax, compliance, and IT due diligence, ClearView Healthcare Partners advised on commercial due diligence, and Ares Credit funds provided committed debt financing in support of the transaction.

Jefferies acted as lead financial advisor to Swixx Biopharma and its shareholders in connection with the transaction. Centerview Partners also served as a financial advisor. Walder Wyss is acting as the lead legal counsel to Swixx Biopharma, supported by NautaDutilh. EY provided advisory on financial, tax, compliance, and legal vendor due diligences (VDD), while BCG supported with commercial VDD.

About Swixx Biopharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, CNS, specialty and vaccines talent under one roof, Swixx Biopharma entered 2026 with more than 1,700 employees on board. For more information about Swixx, please visit: www.swixxbiopharma.com.



About SK Capital

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, material sciences, and specialty ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital has raised funds with over \$9 billion in capital commitments since its inception. For more information, please visit www.skcapitalpartners.com.



About Bain Capital Life Sciences

Bain Capital Life Sciences was founded in 2016 and builds on Bain Capital's four decades of healthcare and life sciences investing across private equity, public equity, credit, venture capital, and real estate. Bain Capital Life Sciences invests in biopharmaceutical, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that drive medical innovation to improve the lives of patients with unmet medical needs. For more information, please visit www.baincapitallifesciences.com.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

About Mérieux Equity Partners

Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.6bn of AuM.

Mérieux Participations 4 is a 2021 vintage fund that has completed 12 healthcare investments in Europe, including Swixx Biopharma.

Swixx Group investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

